dc.creatorVanaerschot, Manu
dc.creatorDumetz, Franck
dc.creatorRoy, Syamal
dc.creatorPonte-Sucre, Alicia
dc.creatorArevalo, Jorge
dc.creatorDujardin, Jean Claude
dc.date2014-11-17T22:54:15Z
dc.date2014-11-17T22:54:15Z
dc.date2014-11-17
dc.date.accessioned2022-10-28T01:02:33Z
dc.date.available2022-10-28T01:02:33Z
dc.identifier1478-7210
dc.identifier1744-8336
dc.identifierhttp://hdl.handle.net/10872/7662
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4941575
dc.descriptionTwo major leishmaniasis treatments have shown a significant decrease in effectiveness in the last few decades, mostly in the Indian subcontinent but also in other endemic areas. Drug resistance of Leishmania correlated only partially to treatment failure (TF) of pentavalent antimonials, and has so far proved not to be important for the increased miltefosine relapse rates observed in the Indian subcontinent. While other patient- or drug-related factors could also have played a role, recent studies identified several parasite features such as infectivity and host manipulation skills that might contribute to TF. This perspective aims to discuss how different parasitic features other than drug resistance can contribute to TF of leishmaniasis and how this may vary between different epidemiological contexts
dc.descriptionEuropean Commission (Kaladrug-R, FP7-222895), the Belgian Development Cooperation (FA3 II VL control and FA3 project 95502), the Belgian Science Policy Office (TRIT, P7/41), the Flemish Fund for Scientific Research (G.0.B81.12), the Alexander von Humboldt Foundation (CDCHUCV PI-09-8717-2013/1) and the Universidad Central de Venezuela Council for Research (PG-09-8646-2013/1).
dc.languageen
dc.relationExpert Reviews Anti Infective Therapy;
dc.subjectLeihsmania
dc.subjectEpi genetics
dc.subjectDrug resistance
dc.subjectLeishmanicidal drugs
dc.titleTreatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
dc.typeArticle


Este ítem pertenece a la siguiente institución